CDB 2914

OBJECTIVE To evaluate the efficacy and tolerability of the P receptor modulator CDB-2914 (Ulipristal, CDB). DESIGN Randomized… Expand

OBJECTIVE To test potential contraceptive mechanisms of the selective P receptor modulator CDB-2914 in the early luteal phase… Expand

OBJECTIVE To evaluate whether 3-month administration of CDB-2914, a selective progesterone receptor modulator, reduces leiomyoma… Expand

Effects of progesterone receptor modulator CDB-2914 on the expression of the extracellular matrix (ECM) components were examined… Expand

BACKGROUND This study was conducted to evaluate the effects of graded concentrations (10(-8), 10(-7) and 10(-6) M) of… Expand

In determining the biological profiles of various antiprogestins, it is important to assess the hormonal and antihormonal… Expand

CDB-2914 (17 alpha-acetoxy-11 beta-[4-N,N-dimethylaminophenyl]-19-norpregna-4,9-diene-3,20-dione) is a 19-norprogesterone… Expand

BACKGROUND Progesterone receptor modulators have potential therapeutic use in progesterone-dependent conditions such as… Expand

To obtain selective antiprogestins, we have examined the in vitro antiprogestational/antiglucocorticoid properties of two novel… Expand

Previous studies in women have shown that the antiprogestin mifepristone delays or inhibits folliculogenesis. The purpose of this… Expand